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doi:10.1016/j.jmii.2012.05.004Background: Hetero-resistant vancomycin intermediate Staphylococcus aureus (hVISA)
emerges worldwide in recent decade. The purpose of this study was to investigate the glyco-
peptide usage trend, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA)
with reduced vancomycin susceptibility, the susceptible rates to newer antimicrobials, molec-
ular epidemiology, clinical characteristics, as well as patient outcome among S. aureus bacter-
emia cases in a Taiwanese medical center.
Methods: From March to December 2009, among 118 S. aureus blood isolates in a Taiwanese
medical center, 62 MRSA isolates were screened for hVISA by Etest macromethod and further
confirmed with modified population analysis profiling method. Molecular typing of hVISA
isolates was performed.
Results: Five (4.2%) isolates were hVISA. Compared with non-hVISA MRSA, hVISA isolates had
higher resistant rates to ciprofloxacin, gentamicin, trimethoprim/sulfamethoxazole, andof Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung City,
du.tw (P.-L. Lu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
436 S.-Y. Lin et al.tetracycline. Among the MRSA infected, patients infected with hVISA had a higher in-hospital
mortality rate than non-hVISA group (60% vs. 17.5%, p Z 0.025). All hVISA isolates were noso-
comial and had different pulsed field gel electrophoresis pulsotype. Four hVISA isolates carried
type III staphylococcal cassette chromosome mec (SCCmec) and the remaining isolate carried
SCCmec type II. Three of the 5 hVISA isolates belonged to sequence type 239, which is the most
common type in Taiwan. Glycopeptide usage increased in the study hospital; however, these
hVISA-infected patients did not receive glycopeptide treatment in the recent 6 months.
Conclusion: Our results suggested hVISA might have disseminated in the hospital before we
observed this highest hVISA rate in Taiwan and increasing glycopeptide usage might serve as
selection pressure. Measures to prevent the transmission of MRSA with reduced vancomycin
susceptibility and to treat such infection were urgently needed.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Infections caused by methicillin-resistant Staphylococcus
aureus (MRSA) with reduced susceptibility to vancomycin
have emerged. Very rarely vancomycin resistant S. aureus
(VRSA; Minimal inhibitory concentration (MIC) 16 mg/ml)
was isolated. The more commonly encountered were
vancomycin-intermediate S. aureus (VISA; MIC: 4e8 mg/ml)
and hetero-resistant vancomycin-intermediate S. aureus
(hVISA) whose vancomycin MIC was no more than 2 mg/ml
but with subpopulations of MRSA with intermediate vanco-
mycin resistance. Although not all clinical studies about
hVISA revealed its significant impact on mortality
outcome,1,2 hVISA causes concerns in treatment failure in
glycopeptide therapy and the increased medical cost.3,4
The incidence of hVISA among MRSA has increased during
the past two decades from 2.2% to 8.3% in Detroit5 while
the hVISA frequency was stable in other United States
studies.6,7 The rate of hVISA decreased in a France study
from 2000 to 2007.8 The above revealed the trend of hVISA
differed in different areas. An Asia surveillance study on
MRSA from 1997 to 2000 reported that hVISA rate was 4.3%
(ranged from 0 to 8.2% among countries)9 that indicated the
hVISA prevalence varied in different Asia countries. The
rate of hVISA among MRSA in China in 2005 was as high as
15.7%.10 Differently, hVISA had been first isolated in Taiwan
in 2002.11 The prevalence rates of VISA and hVISA among
MRSA were 0.7% and 0.2%, respectively, in Taiwan in 2003.12
To understand the updated epidemiology of MRSA with
reduced vancomycin susceptibility in Taiwan,we investi-
gated the glycopeptide usage trend, prevalence of MRSA
with reduced vancomycin susceptibility, the susceptibility
rates to newer antimicrobials, molecular epidemiology,
clinical characteristics as well as patient outcome among
S. aureus bacteremia cases in a Taiwanese medical center.
Methods
From March to December, 2009, patients with S. aureus
bacteremia at a Taiwanese medical center were reviewed
for their medical history and clinical characteristics. Prior
antimicrobial drug exposure was traced up to 6 months
before bacteremia. Healthcare associated infection and
community acquired infection were defined according tothe U.S. Centers for Disease Control and Prevention defi-
nition.13 Comorbidity was assessed by the Charlson
comorbidity index.14 Persistent MRSA bacteremia was
defined by positive cultures at least one week after glyco-
peptide treatment. The glycopeptide use data in the
hospital from 2003 to 2009 was expressed as defined daily
dose (DDD) per 1000 patient-days.15
Antimicrobial susceptibility testing
All S. aureus isolates were tested for susceptibility to
antimicrobial agents using the Vitek 2 system. The inter-
pretation of susceptibility followed Clinical and Laboratory
Standards Institute (CLSI) guidelines.16 The vancomycin and
daptomycin MIC of all MRSA isolates were determined using
standard Etest methods (protocol EAS 003 on AB Biodisk
website). Isolates with vancomycin by Etest (AB Biodisk,
Solna, Sweden) MIC more than 2 mg/ml were further tested
with broth microdilution method. The susceptibility inter-
pretation for fusidic acid is according to the European
Committee on Antimicrobial Susceptibility Testing (ECAST)
clinical MIC breakpoints that >1 mg/ml is resistant.
Method of hVISA screening with Etest
macromethod
Colonies isolated from overnight growth on trypticase soy
agar plate containing 5% sheep blood were inoculated into
brain heart infusion (BHI) broth to achieve 2 McFarland
turbidity. A total of 200 ml of the suspension was dispensed
onto BHI agar. Vancomycin and teicoplanin Etest strips were
placed on the plate surface incubated at 35 C and read at
24 and 48 hours. hVISA was suspected when vancomycin and
teicoplanin MICs  8 mg/ml or teicoplanin MIC  12 mg/ml.
Controls run with each procedure included S. aureus strains
American Type Culture Collection (ATCC) 29213 (vancomy-
cin susceptible) and ATCC 700698 (hVISA; Mu3).17
Modified population analysis profilingearea
under the curve method
All MRSA isolates were assessed by the modified population
analysis profilingearea under the curve (PAP-AUC) method
Table 1 Antimicrobial resistance rates of MSSA and MRSA among Staphylococcus aureus blood isolates
MSSA (n Z 56) MRSA (n Z 62) p value
Ciprofloxacin 2 (3.6%) 29 (46.8%) <0.0001
Fusidic acid 0 (0%) 1 (1.6%) 1.000a
Gentamicin 2 (3.6%) 30 (48.4%) <0.0001
Erythromycin 2 (3.6%) 56 (93.3%) <0.0001
Moxifloxacin 2 (3.6%) 23 (37.1%) <0.0001a
Rifampicin 1 (1.8%) 6 (9.7%) 0.117a
Ampicillin/sulbactam 2 (3.6%) 61 (98.4%) <0.0001
Trimethoprim/sulfamethoxazole 2 (3.6%) 19 (30.6%) <0.0001
Tetracycline 32 (57.1%) 30 (48.4%) 0.342
Teicoplanin 0% 0% -
Vancomycin 0% 0% -
Linezolid 0% 0% -
Daptomycin 0% 0% -
MRSA Z methicillin-resistant Staphylococcus aureus; MSSA Z methicillin-sensitive Staphylococcus aureus.
a By Fisher’s exact test.
hVISA in Taiwan 437in duplicate.18 Isolates were defined as hVISA if they had
a PAP-AUC ratio between 0.9 and 1.3 compared with the
Mu3 reference strain (ATCC 700698).
Staphylococcal cassette chromosome mec,
multilocus sequence typing, and pulsed field
gel electrophoresis typing
Staphylococcal cassette chromosome mec (SCCmec) typing
was performed as previously described.19 Multilocus
sequence typing (MLST) and spa typing by analysis of the
polymorphic X-region of the protein A gene were performed
on hVISA isolates.20,21 Molecular typing of hVISA strains
were performed by using pulsed field gel electrophoresis
(PFGE) with the restriction enzyme SmaI.22
Statistical analysis
P values were calculated by Chi-Square test and Fisher’s
exact test for categorical variables. Linear regressionTable 2 Antimicrobial resistance rates of hVISA and non-hVISA
Non-hVISA MRSA (
Ciprofloxacin 24 (42.1%)
Fusidic acid 1 (1.8%)
Gentamicin 25 (43.9%)
Erythromycin 51 (89.5%)
Moxifloxacin 19 (33.3%)
Rifampicin 4 (7.0%)
Ampicillin/sulbactam 56 (98.2%)
Trimethoprim/sulfamethoxazole 15 (26.3%)
Tetracycline 25 (43.9%)
Teicoplanin 0%
Vancomycin 0%
Linezolid 0%
Daptomycin 0%
hVISA Z hetero-resistant vancomycin intermediate Staphylococcus au
a By Fisher’s exact test.analysis was used for the trend of glycopeptides usage
(DDD/1000 patient-days) with time. A p value < 0.05 was
considered significant.Results
Among 118 patients having S. aureus bacteremia, 62
patients (52.5%) were infected by MRSA. The MICs of van-
comycin by Etest were  1 mg/ml for 53 (45%) isolates,
2 mg/ml for 62 (52.5%) isolates, and 3 mg/ml for three (2.5%)
isolates. No VISA and VRSA was identified as the three
isolates with vancomycin MIC of 3 mg/ml by Etest were
tested to have MIC 2 mg/ml with broth microdilution
method. Seven isolates were preliminarily suspected hVISA
by the Etest macromethod (EMM). Among them, five
isolates were further confirmed to be hVISA with modified
PAP-AUC method. The percentage of hVISA among MRSA
was 8.1% (5/62). The percentage of hVISA among S. aureus
blood isolates was 4.2% (5/118). All hVISA isolates’ MICs to
vancomycin were 2 mg/ml. The difference of antimicrobialamong MRSA isolates
n Z 57) hVISA (n Z 5) p value
5 (100%) 0.018a
0 (0% ) 1.000a
5 (100%) 0.022a
5 (100%) 1.000a
4 (80%) 0.059a
2 (40%) 0.069a
5(100%) 1.000a
4 (80%) 0.028a
5 (100%) 0.022a
0%
0%
0%
0%
reus; MRSA Z methicillin-resistant Staphylococcus aureus.
Table 3 Comparison of characteristics of hVISA and non-hVISA among MRSA isolates
Characteristic hVISA non-hVISA MRSA p value
N Z 5 N Z 57
Mean age (y)  SD 72.8  14.5 65.3  20.0 0.41
Charlson index (age unadjusted) 3.6  1.7 4.0  2.5 0.74
Charlson index (adjusted) 6.6  2.5 6.3  2.7 0.80
Underlying disease
Heart failure 2 (40%) 16 (28.1%) 0.573
End stage renal disease 0 (0%) 8 (14.0%) 0.369
Diabetes 3 (60%) 25 (43.9%) 0.487
Liver cirrhosis 1 (20%) 8 (14.0%) 0.717
Malignancy 1 (20%) 14 (24.6%) 0.819
Prior S. aureus infection 0 (0%) 6 (10.5%) 0.445
Prior MRSA infection 0 (0%) 8 (14.0%) 0.369
Outcome
ICU stay 4 (80%) 22 (38.6%) 0.07
Hospital duration (d) 32.2  23.9 32.3  43.5 0.99
Persistent bacteremia (> 7 d) 1 (20%) 8 (14%) 0.717
In-hospital mortality 3 (60%) 10 (17.5%) 0.025
hVISA Z hetero-resistant vancomycin intermediate Staphylococcus aureus; ICU Z intensive care unit; MRSA Z methicillin-resistant
Staphylococcus aureus; SD Z standard deviation.
Figure 1. Pulsotypes of the hVISA isolates. Molecular typing
with pulsed field gel electrophoresis. Pulsotypes were analyzed
to deduce a dendrogram with the unweighted pair group
method using the arithmetic average clustering technique
after calculation of similarities using Pearson correlation
coefficient between every pairs. Isolates from five hVISA cases:
isolate number 48 and 50 were from the same case; 120 and
121 (the same case); 155, 158 and 159 (the same case); 59; and
94. Isolate numbers 41 and 43 (the same case), 92, and 154
were non-hVISA isolates randomly selected from the study.
ATCC: S. aureus strain ATCC 29213; hVISA Z hetero-resistant
vancomycin intermediate Staphylococcus aureus.
438 S.-Y. Lin et al.resistance rates between MRSA and Methicillin-sensitive
Staphylococcus aureus (MSSA) isolates was presented in
Table 1. All these isolates were susceptible to vancomycin,
teicoplanin, daptomycin and linezolid. Only one (1/118,
0.85%) isolate is resistant to fusidic acid. Significant
differences in antimicrobial resistant rates to ciprofloxacin,
gentamicin, erythromycin, moxifloxacin, ampicillin/sul-
bactam, and trimethoprim/sulfamethoxazole were
observed between MRSA and MSSA (Table 1). Among MRSA
isolates, hVISA had significantly higher resistant rates to
ciprofloxacin, gentamicin, trimethoprim/sulfamethoxazole
and tetracycline (Table 2).
Patients with hVISA bacteremia were not significantly
different from those with non-hVISA bacteremia in terms of
age, underlying diseases and Charlson comorbidity index.
Among MRSA patients, hVISA patients had a higher in-
hospital mortality rate compared these with non-hVISA
(Table 3). All the five hVISA infections were nosocomial.
None of the five hVISA cases had prior S. aureus or MRSA
infection and no glycopeptide exposure in 6 months before
the bacteremia occurred. All the hVISA isolates from the
same patient had the same PFGE pulsotype. These five
hVISA strains from five patients had five different pulso-
types (Fig. 1). Four of the five hVISA strains belonged to
SCCmec type III and the other is SCCmec type II. The only
SCCmec II strain is of MLST type ST5. Among the four
SCCmec III strains, two are of ST239, one is of ST239 single
locus variant (SLV, glpF1:262 T to C), one is of ST900.
Except that one of the isolate’s spa type is not typable,
three of four SCCmec III strains are of spa type 037 and the
only SCCmec II strain is of spa type 002.
The annual DDD of glycopeptide in the hospital
increased from 296 in 2004 to 385 in 2009. The DDD/1000
patient-days of glycopeptide increased significantly from
0.71 in 2004 to 0.95 in 2009 (p valueZ 0.023). These results
are shown in Fig. 2.Discussion
The various prevalence rates of hVISA and VISA in Asian
countries were summarized in Table 4. The highest hVISA
prevalence rate among MRSA blood isolates in Asia was
13.1% in China, followed by 12.5% in Singapore. Our results
revealed the rate of hVISA to be 8.1% among MRSA blood
isolates (4.2% of S. aureus blood isolates) in 2009. To our
Figure 2. The glycopeptide use per 1000 patient-days each
year in the study hospital from 2003 to 2009.
hVISA in Taiwan 439knowledge, it is the latest and highest rate of hVISA in
Taiwan that suggests the emergence of hVISA in Taiwan.
In this study, the five hVISA isolates possess either SCCmec
III or II that are more common in nosocomial MRSA
strains.22,23 Reviewing these five cases’ medical history also
proved the nosocomial infections. We observed the trend of
hVISA with more ICU stay and higher mortality. Although
a higher prevalence of hVISA may be related to nosocomial
clonal spread,24 molecular typing with PFGE identified no
closely related pulsotypes of hVISA in the hospital during the
study period. Different from that hVISA in a Singapore
hospital had closely related pulsotypes,25 hVISA isolates in
the study had unrelated pulsotypes. Because of the
increasing frequency of MRSA infection in Taiwan,23 glyco-
peptide use increased in recent years.Whenweobserved the
emergence of hVISA in the hospital,we noticed the increased
glycopeptide use that may served as selection pressure
(Fig. 2). However, our five hVISA patients did not have
glycopeptide exposure in the recent 6 months, which sug-
gested these hVISA strains already circulated in the hospital
and patients’ hVISA might be from unidentified hVISA colo-
nizers. The threat of hVISA is therefore not limited to thoseTable 4 Prevalence rates of hVISA and VISA among MRSA isolat
Country Year No. of MRSA
isolates
Specimen hVISA am
MRSA
Asia 1997e2000 1349 ND 4.3%
Japan 1997 6625 ND 0
Hong Kong 1997e1998 52 Blood 5.8%
India 1999 120 Various ND
Korea 1999e2001 439 Various 0
China 2002e2007 200 Blood 13.1%
Taiwan 2003 1000 Various 0.7%
Singapore 2005e2006 56 Blood 12.5%
Thailand 2002e2003 533 ND 0.8%
2006e2007 361 2.2%
Southern India ND 102 ND ND
Taiwan 2009 62 Blood 8.1%
hVISA Z hetero-resistant vancomycin intermediate Staphylococcus au
resistant Staphylococcus aureus.patients with glycopeptides use. The findings also emphasize
the need of infection control measures to prevent MRSA
transmission.
In this study, hVISA was not associated with persistent
bacteremia as previously reported,2 which may be owing to
the small case number of hVISA in the study that made us
unable to observe a significant difference. Although the age
in both hVISA and non-hVISA groups were not significantly
different, the trend to be more aged of hVISA group may
affect the clinical outcome. In our study, hVISA infection
was associated with a higher in-hospital mortality rate and
a higher rate of ICU stay among MRSA isolates. However, the
impact of hVISA on mortality is controversial.1,3,4,12 Among
S. aureus, a meta-analysis revealed that hVISA was associ-
ated with a similar 30-day mortality compared to
vancomycin-susceptible S. aureus infections.26 As the hVISA
rate among S. aureus is relatively low, a large case number
is required to identify its impact on mortality among S.
aureus.
Multiple drug resistance raised a serious concern for
MRSA when compared with MSSA. Among MRSA blood
isolates, hVISA isolates had higher resistance rates to
ciprofloxacin, gentamicin, trimethoprim/sulfamethoxazole
and tetracycline that indicated the more limited antimi-
crobial options for hVISA. Our results revealed these hVISA
isolates were all susceptible to daptomycin, linezolid and
tigecycline; those could be treatment options.
ST239 MLST type is the most predominant MRSA clone in
Taiwan and ST59-SCC mec IV or ST59-SCCmecV is the
second.23,27 In the study, three of the 5 hVISA isolates
belong to ST239 and had SCCmec III. The appearance of
hVISA in the major MLST clone warrants close monitor in
fear of the possible expanding hVISA epidemic in Taiwan.
The limitations of our study include: (a) because of the
retrospective design, we did not categorize all cases of S.
aureus infection to be of community-acquired infection or
healthcare associated infection. The number of glycopep-
tide exposure would be underestimated because some
patients may have been exposed to it in other hospitals,
and (b) hVISA isolates in the study were of ST5 and ST239
that both usually were resistant to ciprofloxacin andes in Asia
ong VISA among
MRSA
hVISA among
S. aureus
VISA among
S. aureus
Reference
0 NA NA 9
0 0 0 28
0 1.8% 0 29
33.3% ND ND 30
0 0 0 31
0.05% 0 0 10
0.2% 0 0 32
5.4% 0 0 1
0 0 0 33
0 0
0.9% ND 0.7% 34
0 4.2% 0 This study
reus; NA Z not applicable; ND Z no data; MRSA Z methicillin-
440 S.-Y. Lin et al.gentamicin in Taiwan and China.10,35 Although we observed
hVISA isolates were more resistant to ciprofloxacin,
gentamicin, trimethoprim/sulfamethoxazole, and tetracy-
cline than non-hVISA isolates, the resistant pattern may be
related to the characteristics of MLST types.
In conclusion, 8.1% MRSA blood isolates in the Taiwan
hospital were hVISA that caused nosocomial infection with
a higher in-hospital mortality rate. Increasing glycopeptide
usage may serve as selection pressure for the emergence of
hVISA. That hVISA isolates were not from patients with prior
glycopeptide use and not of closely related pulsotype
suggest the existence and transmission of hVISA before this
surveillance. Measures to prevent the expanding trans-
mission of MRSA with reduced vancomycin susceptibility
and to treat the related infections are urgently needed.Acknowledgments
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